DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Mowbray, CEORCID logo, Braillard, SORCID logo, Glossop, PAORCID logo, Whitlock, GA, Jacobs, RTORCID logo, Speake, J, Pandi, B, Nare, B, Maes, L, Yardley, V, Freund, Y, Wall, RJORCID logo, Carvalho, S, Bello, D, Van den Kerkhof, M, Caljon, G, Gilbert, IHORCID logo, Corpas-Lopez, V, Lukac, I, Patterson, S, Zuccotto, FORCID logo and Wyllie, SORCID logo (2021). DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. [Dataset]. ACS Publications, Washington, DC, USA. https://doi.org/10.1021/acs.jmedchem.1c01437.s004
Copy

DNDI-6148 has been declared a preclinical candidate for the treatment of visceral leishmaniasis. This collection contains documentation (S1), string data for all compounds (S2), DNDI-6148 rat and dog pharmacokinetic data (S3) and Compound 23 docked into LdCPSF3 (S4). Files may be accessed through the Collection Record held on Figshare.

Keywords

Visceral leishmaniasis, Parasitic diseases, Benzoxaborole chemotype, Antileishmanial activity, DNDI-6148


Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core (with Type as Type) MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON METS MODS RDF+N3 RDF+N-Triples RDF+XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads